Domestic bunanselin will be on the market soon to promote the market of psychotherapy drugs in China

At the same time, bunanselin orally disintegrating tablets (class 3.1) of Beijing Dezhong Wanquan Pharmaceutical Technology Development Co., Ltd were approved on November 27, 2014 - to be certified; its clinical acceptance number is cxhl1400827 / cxhl1400828 Data shows that in 2013, the number of psychotropic drugs in sample hospitals of 16 key cities in China was 1.131 billion yuan, an increase of 13.14% compared with the previous year, including antipsychotics and Zhenjing anding, of which 70% were antipsychotics It is speculated that the domestic market scale of this kind of drugs can reach 8 billion yuan Brenanserin is a new type of oral D2 / 5-HT2 receptor blocker developed by Sumitomo Pharmaceutical Co., Ltd in Japan It has a completely innovative chemical structure and is used in antipsychotic drugs Now it is on the market in Japan and is in phase III clinical practice in the United States and Europe Bunanserine belongs to 5-hydroxytryptamine and dopamine antagonists, and is the second generation of new antipsychotic drugs The drug has the same dopamine D2 receptor blocking effect as haloperidol, but also has a strong blocking effect on 5-HT2A The selectivity of the two receptors is stronger than other antipsychotics Compared with other antipsychotic drugs, bunanserine has a special effect, which can alleviate the cognitive impairment of schizophrenics, and has fewer side effects than the clinical antipsychotic drugs in Europe and America Research shows that bunanserine and risperidone have the same clinical effect, and the two groups of treatment are beneficial to both immediate and delayed oral memory In addition, bunanserine has a special effect on patients' attention and response speed, which can better alleviate the cognitive disorders of schizophrenics In addition, bunanserine has a special mechanism for patients' attention and response speed At present, according to the CFDA official website, there are 8 development units of bunanselin, including Zhejiang Huahai Pharmaceutical Co., Ltd., Jiangsu Haosen Pharmaceutical Co., Ltd., Beijing new leading pharmaceutical technology development, Hebei Guolong Pharmaceutical Co., Ltd., Taizhou Wanquan Pharmaceutical Technology Co., Ltd., Tianjin hankang Pharmaceutical Biotechnology Co., Ltd., Jinan banuo Pharmaceutical Technology Development Co., Ltd., Chengdu high tech Zone pharmaceutical biotechnology research institute, etc Olanzapine and risperidone are widely used in competitive drug market Olanzapine, as the largest antipsychotic drug in the market share, is reported to have an annual global sales volume of about 5 billion US dollars in 2012, and an annual sales volume of about 1.5 billion yuan in China Olanzapine is a new antipsychotic drug developed by Lilly company in the United States It was listed in the United States and the European Union in 1996, and its trade name is zaeple Olanzapine retains the main advantages of clozapine as an atypical antipsychotic drug, and has no blood toxicity Therefore, olanzapine has become one of the most commonly used antipsychotic drugs in the clinic The indication of olanzapine is maintenance therapy for acute schizophrenia and schizophrenia, and it can also be used for manic episode of tardive dyskinesia and bi-directional affective disorder In recent years, it has been found that olanzapine can cause metabolic abnormalities and increase blood sugar, which hinders the use of olanzapine in maintenance therapy According to Lilly's financial report, olanzapine's global market in 2013 was US $1.195 billion, down 29.79% from the previous year CFDA approved the import of olanzapine preparations from Lilai company and Dr redI laboratory in India, and approved the production and listing of two domestic pharmaceutical companies, Jiangsu Haosen Pharmaceutical Co., Ltd and Changzhou Huasheng Pharmaceutical Co., Ltd According to domestic data, olanzapine used in sample hospitals in 16 key cities in 2013 was 308 million yuan, an increase of 12.29% over the previous year Among the top three are Suzhou Lilai's "zaeple" accounting for 55.51%, Jiangsu Haosen pharmaceutical's "olanning" accounting for 42.38%, Changzhou Huasheng pharmaceutical's "Ximin" accounting for 2.11% Another antipsychotic drug in China is risperidone Risperidone, a benzoisoxazole derivative, is a new generation of antipsychotics Risperidone is a selective monoaminergic antagonist with unique properties It has high affinity with 5-HT2 receptor of serotonin and D2 receptor of dopamine Risperidone can also bind to adrenergic receptor and bind to H1 histamine receptor and α 2-adrenergic receptor with low affinity Risperidone does not bind to cholinergic receptors Risperidone is a powerful D2 antagonist, which can improve the positive symptoms of schizophrenia At the same time, risperidone is very effective in the treatment of mania But it causes less motor inhibition and tetanic syncope than classic antipsychotics The balance of 5-hydroxytryptamine and dopamine antagonistic effects on the central system can reduce the possibility of extrapyramidal side effects, and extend its therapeutic effect to the negative and emotional symptoms of schizophrenia The indication is acute and chronic schizophrenia, which has a better therapeutic effect on the obvious positive symptoms such as hallucination, delusion, thinking disorder, hostility, doubt and the obvious negative symptoms such as slow response, emotional indifference and social indifference; it can also alleviate the depression and anxiety emotional symptoms related to schizophrenia Risperidone is a drug listed by Johnson & Johnson company in the United States Its trade name is vistone In March 2011, the European Commission approved the long-term injection xeplion palmitate developed by Janssen cilag international for intramuscular injection once a month to treat schizophrenia According to the financial report of Johnson & Johnson, Risperdal consta is the driving force of market development In 2007, Risperdal of Johnson & Johnson reached a peak of 4.556 billion US dollars At present, the main foreign varieties are Risperdal consta, while the general dosage of Risperdal has been decreasing In 2013, the global market of risperidone was US $1.318 billion, down 7.51% year on year CFDA has approved the listing of 10 domestic risperidone producers According to domestic data, risperidone used in 16 sample hospitals in key cities in 2013 was 82 million yuan, down 7.74% year on year Among them, "Weisitong" of Xi'an YANGSEN accounts for 68.73%, the "Ketong" of Jilin West Point pharmaceutical accounts for 6.43%, the "zhuofu" of Qilu pharmaceutical accounts for 5.18%, the "silishu" of Jiangsu Enhua pharmaceutical accounts for 4.94%%, and the "Danke" of Changzhou four pharmaceutical accounts for 4.22% The reason for the slight decline in the market is mainly due to the decline of drug use and side effects in some people New antipsychotics need to be launched to achieve the goal of differential treatment Schizophrenia is a kind of severely crippling mental disorder Although the prevalence rate is only 1%, after the treatment of the first onset patients, the recovery rate is less than 20%, and the recurrence rate is very high Within two years, the recurrence rate reaches 80% The main drugs used to treat schizophrenia are traditional anti schizophrenia drugs and atypical anti schizophrenia drugs With the deepening of clinicians' cognition of schizophrenia and the continuous influx of foreign anti schizophrenia drugs, China's anti schizophrenia drugs have made great progress in recent years, and the market of anti schizophrenia drugs is increasing year by year Although there is a big gap with the global market, there is still a great room for growth and momentum in terms of the current incidence and epidemic trend of schizophrenia in China.